"Michael R. Sperling, MD, is a Epilepsy specialist with the department of Neurology at Jefferson Health."

During the past decade, Thomas Jefferson University, Comprehensive Epilepsy Center conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 4 clinical trials were completed, i.e. on average, 133.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Thomas Jefferson University, Comprehensive Epilepsy Center" #1 sponsor was "Marinus Pharmaceuticals" with 2 trials, followed by "SK Life Science, Inc." with 2 trials sponsored, "Pfizer" with 1 trials sponsored, "The Epilepsy Study Consortium" with 1 trials sponsored and "Xenon Pharmaceuticals Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Thomas Jefferson University, Comprehensive Epilepsy Center" #1 collaborator was "Eisai Inc." with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator, "H. Lundbeck A/S" with 1 trials as a collaborator, "Johnson & Johnson Pharmaceutical Research & Development, L.L.C." with 1 trials as a collaborator and "Novotech Health Holdings Pte. Ltd." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Thomas Jefferson University, Comprehensive Epilepsy Center" are "Partial Epilepsy" (2 trials), "Drug Resistant Partial Onset Seizure" (1 trials), "Epilepsy" (1 trials), "Epilepsy, Complex Partial" (1 trials) and "Focal Epilepsy" (1 trials). Many other conditions were trialed in "Thomas Jefferson University, Comprehensive Epilepsy Center" in a lesser frequency.

Most popular intervention types in "Thomas Jefferson University, Comprehensive Epilepsy Center" are "Drug" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "YKP3089" (2 trials), "ganaxolone" (2 trials), "Lorazepam" (1 trials) and "PF-06372865" (1 trials). Other intervention names were less common.

The vast majority of trials in "Thomas Jefferson University, Comprehensive Epilepsy Center" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Thomas Jefferson University, Comprehensive Epilepsy Center". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Thomas Jefferson University, Comprehensive Epilepsy Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Thomas Jefferson University, Comprehensive Epilepsy Center, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".